Promoting resolution of acute clinical manifestations of mucocutaneous HSV infections in immunocompromised patients. Severe 1st episode primary or non-primary genital herpes in immune competent patients, acute manifestations of varicella zoster virus infection in immunocompromised patients, shingles (varicella zoster virus infection) in immune competent patients who show very severe acute local or systemic manifestations of the disease, herpes simplex encephalitis.
Not to be inj as rapid or bolus IV inj, IM or SC. Severe local inflammatory reactions. Patients w/ underlying neurological abnormalities, significant hypoxia or serious electrolyte abnormalities; thrombotic thrombocytopenic purpura/haemolytic uraemic syndrome. Development of resistant HSV strains. Manifestations of neurological reactions to cytotoxic drugs. Concomitant use of other nephrotoxic drugs, interferon or intrathecal methotrexate. Ensure adequate hydration. Renal impairment, preexisting renal disease. Hepatic impairment. Not to be used during pregnancy. Lactation. Elderly.
Local inj site inflammation; inj site phlebitis; nausea & vomiting; elevation of transaminases, rapid increased in serum urea nitrogen & creatinine; hives, itching, rashes.
J05AB01 - aciclovir ; Belongs to the class of nucleosides and nucleotides excluding reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Manage Account
Change Password
Sign Out
